MedTrace Logo

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

NCT02999477 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for hormone receptor positive breast cancer.

The interventions involved in this study are:

* Pembrolizumab (MK-3475; Keytruda™)
* Nab-Paclitaxel (Abraxane

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab will be administered in clinic every three weeks.

DRUG

Nab-Paclitaxel

Nab-Paclitaxel will be administered in clinic every week.

PROCEDURE

Biopsy

Biopsies for research purposes will be performed at three separate timepoints during treatment.

Sponsors & Collaborators

Principal Investigators

  • Adrienne Gropper Waks, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-23
Primary Completion
2022-11-20
Completion
2026-01-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02999477 on ClinicalTrials.gov